Uncategorized

Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno

Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno

Published

on

Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is looking to establish its name in the cardiometabolic space.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version